Experts fear U.S. won’t see next COVID surge coming
NEW YORK — As coronavirus infections rise in some parts of the world, experts are watching for a potential new COVID-19 surge in the U.S. — and wondering how long it will take to detect.
Despite disease-monitoring improvements over the last two years, they say, some recent developments don’t bode well:
- As more people take rapid COVID-19 tests at home, fewer people are getting the gold-standard tests that the government relies on to track case counts.
- The Centers for Disease Control and Prevention will soon use fewer labs to look for new variants.
- Health officials are increasingly focusing on hospital admissions, which rise only after a surge has arrived.
- A wastewater surveillance program remains a patchwork that cannot yet be counted on for the data needed to understand coming surges.
- White House officials say the government is running out of funds for vaccines, treatments and testing.
“We’re not in a great situation,” said Jennifer Nuzzo, a Brown University pandemic researcher.
Scientists acknowledge that the wide availability of vaccines and treatments puts the nation in a better place than when the pandemic began, and that monitoring has come a long way.
For example, scientists this week touted a 6-month-old program that tests international travelers flying into four U.S. airports. Genetic testing of a sample on Dec. 14 turned up a coronavirus variant — the Omicron subvariant known as BA.2 — seven days earlier than any other reported detection in the U.S.
More good news: U.S. cases, hospitalizations and deaths have been falling for weeks.
But it’s different elsewhere. The World Health Organization this week reported that the number of new coronavirus cases increased two weeks in a row globally, likely because COVID-19 prevention measures have been halted in numerous countries and because BA.2 spreads more easily.
Some public health experts aren’t certain what that means for the U.S.
BA.2 accounts for a growing share of U.S. cases, the CDC said — more than one-third nationally and more than half in the Northeast. Small increases in overall case rates have been noted in New York and in hospital admissions in New England.
Coronavirus samples in L.A. County earlier this month showed the Omicron BA.2 subvariant on the rise, amid a federal stalemate over COVID funds.
Some of the northern U.S. states with the highest rates of BA.2, however, have some of the lowest case rates, noted Katriona Shea of Penn State University.
Dr. James Musser, an infectious disease specialist at Houston Methodist Hospital, called the national case data on BA.2 “murky.” He added: “What we really need is as much real-time data as possible ... to inform decisions.”
Here’s what coronavirus trackers are looking at and what worries scientists about them:
Test results
Tallies of test results have been at the core of understanding the spread of the coronavirus from the start, but they have always been flawed.
Initially, only sick people got tested, meaning case counts missed people who were infected but had no symptoms or were unable to get swabbed.
Home test kits became widely available last year, and demand took off when the Omicron wave hit. But many people who take home tests don’t report results to anyone. Nor do health agencies attempt to gather them.
Californians have been racing to buy at-home testing kits. But chances are that the results aren’t making their way into the public health system.
Mara Aspinall is managing director of an Arizona-based consulting company that tracks coronavirus testing trends. She estimates that in January and February, about 8 million to 9 million rapid at-home antigen tests were being done each day on average — four to six times the number of PCR tests.
Nuzzo said: “The case numbers are not as much a reflection of reality as they once were.”
Hunting for variants
In early 2021, the U.S. was far behind other countries in using genetic tests to look for worrisome virus mutations.
A year ago, the CDC signed deals with 10 large labs to do that genomic sequencing. The agency will be reducing that program to three labs over the next two months.
The weekly volume of sequences performed through the contracts was much higher during the Omicron wave in December and January, when more people were getting tested, and already has fallen to about 35,000. By late spring, it will be down to 10,000, although CDC officials say the contracts allow the volume to increase to more than 20,000 if necessary.
The agency also says turnaround time and quality standards have been improved in the new contracts, and that it does not expect the change will hurt its ability to find new variants.
Outside experts expressed concern.
“It’s really quite a substantial reduction in our baseline surveillance and intelligence system for tracking what’s out there,” said Bronwyn MacInnis, director of pathogen genomic surveillance at the Broad Institute of MIT and Harvard.
Sewage surveillance
An evolving monitoring system is looking for signs of coronavirus in sewage, which could potentially capture brewing infections.
Researchers have linked wastewater samples to the number of positive coronavirus tests a week later, suggesting health officials could get an early glimpse at infection trends.
Many public health officials say the success of COVID-19 sewage surveillance should make it a regular tool in tracking infectious diseases.
Some health departments also have used sewage to look for variants. New York City, for example, detected the Omicron variant in a sample taken on Nov. 21 — about 10 days before the first case was reported in the U.S.
But experts note the system doesn’t cover the entire country. It also doesn’t distinguish who is infected.
“It’s a really important and promising strategy, no doubt. But the ultimate value is still probably yet to be understood,” said Dr. Jeff Duchin, the health officer for Seattle/King County, Wash.
Hospital data
Last month, the CDC outlined a new set of measures for deciding whether to lift mask-wearing rules, focusing less on positive test results and more on hospitalizations.
Hospital admissions are a lagging indicator, given that a week or more can pass between infection and hospitalization. But a number of researchers believe the change is appropriate. They say hospital data is more reliable and more easily interpreted than case counts.
The lag, compared to using test results, also is not as long as one might think. Some studies have suggested many people wait to get tested. And when they finally do, the results aren’t always immediate.
Spencer Fox, a University of Texas data scientist who is part of a group that uses hospital and cellphone data to forecast COVID-19 for Austin, said “hospital admissions were the better signal” for a surge than test results.
If the U.S. public health emergency ends, Americans would be vulnerable to a new coronavirus variant that sparks another COVID-19 surge.
There are concerns, however, about future hospital data.
If the federal government lifts its public health emergency declaration, officials will lose the ability to compel hospitals to report COVID-19 data, a group of former CDC directors recently wrote. They urged Congress to pass a law that will provide enduring authorities “so we will not risk flying blind as health threats emerge.”
Associated Press writers Lauran Neergaard in Washington and Laura Ungar in Louisville, Ky., contributed to this report.
